Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study

Dear Physicians,

The University of Maryland School of Medicine, Center for Vaccine Development and Global Health (CVD) is conducting a clinical trial of an experimental preventative treatment for individuals who have been exposed to the SARS-CoV-2 (COVID-19) virus in the last four days, either as a household member of a COVID-19 positive individual or as a healthcare professional for a COVID-19 positive individual. The research study will determine if taking hydroxychloroquine prevents COVID-19 infection or symptoms. Participants have an equal chance of receiving hydroxychloroquine or vitamin C.

We are asking you to refer recent (<4 days) household or health care contacts of COVID-19 infected individuals to the study website to obtain more information and contact the study team [www.covid19pepstudy.org](http://www.covid19pepstudy.org). Please see the website for more details.

Thank you for your attention, and please feel free to contact us via email clintrial@som.umaryland.edu if you would like additional information about our clinical trial.

Sincerely,

Kathleen Neuzil, MD, MPH, FIDSA
Professor of Medicine and Pediatrics
Principal Investigator
University of Maryland School of Medicine
Center for Vaccine Development and Global Health
685 West Baltimore Street, Suite 480
Baltimore, Maryland 21201
410-706-6156, clintrial@som.umaryland.edu